Risk of New Indications for Anticoagulants and Thrombolytics in People With Cognitive Impairment: Implications for Anti-Amyloid Therapy.

ABSTRACT:

Objectives

Anticoagulants and thrombolytics may interact with anti-amyloid monoclonal antibodies (mAbs) to increase intracranial hemorrhage risk, so expert guidance recommends against their co-prescription. We aimed to estimate how many people with mild cognitive impairment (MCI) or dementia develop a new cardiovascular indication for anticoagulant and thrombolytic drugs.

Methods

In a longitudinal cohort of adults aged 65 years or older from the Health and Retirement Study (2010-2020) with linked Medicare claims and no previous indication for anticoagulants, cognition was categorized as normal, MCI, or dementia. We fit separate Fine-Gray survival models accounting for competing risk of death to estimate 1-year incidence of atrial fibrillation (AF), deep vein thrombosis (DVT)

SUBMITTER: Parks AL 

PROVIDER: S-EPMC12752935 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature